Familial pancreatic cancer is pancreatic cancer that clusters in families. The formal definition is two or more first degree relatives, a parent, sibling or child, with the disease. It accounts for roughly 5 to 10 percent of all pancreatic cancers. The risk climbs with each affected relative, and when the cancers appear at younger ages.

According to Dr. Sandeep Nayak, Surgical Oncologist in India, “Most pancreatic cancer isn’t inherited, but a real fraction is. When two or more close relatives have had it, that pattern matters. It points to a gene running through the family. Identifying those people early lets us watch them properly, and with pancreatic cancer, finding it early is the whole game.”

A handful of factors decide how strongly pancreatic cancer runs in a family.

• Number of relatives : One affected relative nudges the risk. Two or more first degree relatives pushes it into genuinely high territory.
• Age at diagnosis : Cancers showing up young hint at a stronger inherited driver than the same cancer late in life.
• The genes : Inherited faults in BRCA2, PALB2, ATM and others carry the risk down generations. BRCA2 is the most common culprit.
• Linked cancers : A family history of breast, ovarian or colorectal cancer can raise pancreatic risk too. The genes overlap.

Knowing the pattern shapes how closely someone is watched, and pancreatic cancer care for high risk families starts long before any symptom appears.

Spotting familial risk early changes what’s possible, because this cancer punishes late diagnosis hard.

• Surveillance : High risk people can enter screening programmes, usually MRI or endoscopic ultrasound, to catch changes early.
• The early window : Pancreatic cancer found before it spreads is far more survivable. Surveillance is built around finding that window.
• Genetic testing : Confirming a gene fault tells a whole family who’s at risk and who can be reassured. Clarity for everyone.
• Lifestyle : Smoking multiplies inherited risk sharply. For high risk families, stopping is one of the few levers that genuinely helps.

The reason all this effort matters comes down to pancreatic cancer survival, which shifts dramatically depending on how early the disease is caught.

Dr. Sandeep Nayak is a surgical oncologist with 24 years behind him and a fellowship in laparoscopic and robotic onco-surgery. He treats the full range of pancreatic disease, including robotic Whipple surgery, and works with high risk patients where family history shapes the plan. The approach starts with understanding the family pattern, since a person with inherited risk needs watching, not waiting. That foresight is what catches these cancers in time.

With pancreatic cancer, timing decides almost everything. A tumour found early enough to remove offers a real chance at cure. The same tumour found late rarely does. For families carrying this risk, structured surveillance and an experienced surgical team are what turn an inherited threat into something that can actually be managed.

References

1. Familial pancreatic cancer surveillance strategy — National Library of Medicine
2. Family history and pancreatic cancer risk — National Library of Medicine

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.

Peritoneal mesothelioma is a rare cancer that starts in the lining of the abdomen. That lining, the peritoneum, wraps the abdominal organs, and this cancer grows along it rather than in a single lump. It’s aggressive, and it’s nearly always tied to past asbestos exposure. The trouble is it stays quiet until it’s advanced.

According to Dr. Sandeep Nayak, Surgical Oncologist in India, “Peritoneal mesothelioma is one of the harder cancers to catch early. The symptoms are vague, bloating, abdominal discomfort, and they mimic far more common problems. By the time it’s found, it’s often spread across the peritoneum. But it isn’t untreatable. The right surgery with heated chemotherapy has genuinely changed what’s possible here.”

This cancer has a clear main trigger and a frustratingly quiet presentation.

• Asbestos : The big cause. Fibres swallowed or inhaled years ago lodge in the body and drive the disease decades later.
• Long delay : Mesothelioma can surface 20 to 40 years after exposure. The gap is why many patients never connect the two.
• Vague signs : Abdominal pain, bloating, a swollen belly from fluid, weight loss. None of it screams cancer, so it gets missed.
• Spread pattern : Rather than one tumour, it studs the peritoneum with nodules. That’s what makes it so tricky to treat.

Catching it needs imaging and a biopsy, and HIPEC treatment is the approach that’s reshaped survival for the right patients.

For suitable patients, the modern approach is surgery paired with heated chemotherapy.

• Cytoreduction first : The surgeon removes as much visible disease from the abdomen as possible. The completeness of this drives the outcome.
• Heated chemo : Warmed chemotherapy is then washed through the abdominal cavity to kill what surgery can’t see. That’s the HIPEC part.
• Patient selection : It isn’t for everyone. The extent of spread and overall fitness decide who genuinely benefits from such major surgery.
• The payoff : For well selected patients, this combination has pushed survival from months into years. A real shift.

This is the same approach detailed in our work on cytoreductive surgery and HIPEC for cancers that spread across the peritoneum.

Dr. Sandeep Nayak is a surgical oncologist with 24 years behind him and a fellowship in laparoscopic and robotic onco-surgery. He’s among India’s most experienced HIPEC surgeons, having performed cytoreductive surgery for peritoneal disease from mesothelioma, appendix, colorectal and ovarian cancers. The work starts with honest patient selection, since this surgery only helps when the disease and the patient are right for it. That judgement is where the real expertise sits.

Mesothelioma rewards experience more than almost any cancer. The completeness of cytoreduction is the single biggest factor in how long a patient lives, and that completeness comes down to the surgeon’s skill in the abdomen. A thorough operation followed by HIPEC offers a chance that simply didn’t exist a generation ago.

References

1. Diffuse malignant peritoneal mesothelioma pathway — National Library of Medicine
2. Peritoneal mesothelioma surgical outcomes — National Library of Medicine

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.

A neuroendocrine tumour can be a cancer, but not always. These tumours grow from the body’s hormone producing cells, and they sit on a spectrum. Some are slow, quiet and close to benign. Others are aggressive and clearly malignant. What decides it is the grade and whether the tumour has spread.

According to Dr. Sandeep Nayak, Surgical Oncologist in India, “Neuroendocrine tumours don’t fit the simple cancer or not cancer box. They run from indolent growths that barely move to high grade carcinomas that spread fast. The grade tells us how the cells are behaving, the stage tells us how far they’ve gone. You can’t answer the cancer question without both. That nuance is the whole point with NETs.”

Whether a neuroendocrine tumour counts as cancer comes down to how its cells behave.

• Grade : This measures how fast the cells divide. Low grade ones creep along. High grade ones behave like aggressive cancer.
• Spread : A tumour that’s invaded nearby tissue or reached the liver is malignant, full stop. Containment is the dividing line.
• Differentiation : Well differentiated cells look close to normal and behave better. Poorly differentiated ones are the worrying end.
• Hormone activity : Some NETs pump out hormones and cause symptoms. That doesn’t decide cancer, but it shapes how they’re managed.

Grade and stage together build the full picture, and pancreatic cancer care covers neuroendocrine tumours of the pancreas as part of that work.

NETs are sorted by where they start and how their cells look under the microscope.

• By site : Most arise in the gut, pancreas or lungs. The location shapes symptoms and often the treatment path.
• By grade : Pathologists score them grade 1 to 3. The grade drives the prognosis more than almost anything else.
• Functional or not : Functional NETs secrete hormones and announce themselves. Non functional ones grow silently until found by chance.
• Carcinoid types : Some slow growing NETs were historically called carcinoids. The name lingers, but they’re still neuroendocrine tumours.

This is the same spectrum that separates benign and malignant tumours more broadly, just applied to one particular cell type.

Dr. Sandeep Nayak is a surgical oncologist with 24 years behind him and a fellowship in laparoscopic and robotic onco-surgery. He treats neuroendocrine tumours across the gut and pancreas, where accurate grading and staging decide everything that follows. The approach starts with pinning down exactly what the tumour is and how it’s behaving before any plan is set. A low grade NET and a high grade carcinoma need completely different handling.

Getting the classification right is what separates good NET care from guesswork. A slow growing tumour treated as aggressive means needless intervention. A high grade one underestimated loses precious time. Surgery for well differentiated NETs can be curative, and minimally invasive resection keeps recovery short where the tumour allows it.

References

1. Neuroendocrine tumour epidemiology and outcomes — National Library of Medicine
2. Neuroendocrine tumour overview — National Cancer Institute

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.

A multi-cancer early detection test, or MCED, is a single blood test that screens for many cancers at once. It looks for DNA that tumours shed into the blood, often before any symptom shows. One draw, many cancers checked together. Most of the cancers it covers have no routine screening of their own.

According to Dr. Sandeep Nayak, Surgical Oncologist in India, “The value of an MCED test is reach. Standard screening covers four or five cancers. This casts a far wider net from one blood sample. But a signal isn’t a diagnosis. It points us toward where to look, and the real confirmation still comes from imaging and a tissue biopsy. It’s a starting flag, not the final word.”

It reads the molecular traces cancer leaves in the bloodstream, then narrows down the source.

• Shared signal : Many cancers shed DNA with tell tale changes. The test picks up this common signal across different tumour types.
• Methylation patterns : It reads chemical tags on the DNA, not just the sequence. Those tags hint at which organ the signal came from.
• Signal origin : When something turns up, the test predicts the likely site. That tells doctors where to point the follow up scans.
• One sample : All of it runs off a single blood draw. No prep, no procedure, nothing invasive about the test itself.

It sits within a wider diagnostic and treatment picture, and advanced robotic cancer surgery becomes an option only after proper confirmation of what’s actually there.

The test adds to routine screening rather than standing in for it.

• Filling the gaps : Most cancers have no standard screening at all. MCED reaches some of those, which is where it earns its place.
• Not a replacement : Mammograms, colonoscopy, Pap smears all still matter. This works alongside them, it doesn’t push them aside.
• For higher risk : It’s aimed mostly at older adults and those with raised risk, where the odds of catching something justify it.
• Confirmation always follows : A detected signal triggers imaging and biopsy. Nothing gets called cancer on the blood test alone.

Understanding which tests used for cancer suit a given person is what builds an accurate picture before anything is decided.

Dr. Sandeep Nayak is a surgical oncologist with 24 years behind him and a fellowship in laparoscopic and robotic onco-surgery. His diagnostic approach is precision based, weaving together clinical exam, imaging, tissue biopsy and molecular profiling so nothing slips through. An MCED signal fits into that as a prompt to investigate, never as a conclusion on its own. The test guides the workup. The workup makes the diagnosis.

A flagged signal is only the beginning. What it really buys is a head start, the chance to find a cancer while it’s small and still curable. But it takes a careful workup to turn that signal into an accurate diagnosis, and a clear plan from there. The right follow through is what makes early detection actually mean something.

References

1. Multi-cancer early detection technologies review — National Library of Medicine
2. MCED blood test real-world evidence — National Library of Medicine

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.

A liquid biopsy is a blood test that looks for traces of cancer in the bloodstream. Tumours shed DNA fragments and whole cells into the blood, and this test picks them up from a simple sample. No needle into the tumour, no tissue removed. It reads what the cancer leaves behind in circulation.

According to Dr. Sandeep Nayak, Surgical Oncologist in India, “A liquid biopsy doesn’t replace the tissue biopsy, it adds to it. When tissue is hard to reach or we need to track how a cancer is behaving over time, a blood draw tells us things a one off sample can’t. It’s most useful for watching treatment response and catching resistance early. The tumour shows its hand in the blood.”

The test hunts for tumour material that’s broken loose and entered the blood.

• Tumour DNA : Cancers shed fragments of their DNA, called ctDNA. The test reads these for mutations that name the cancer.
• Whole cells : Circulating tumour cells break off the primary tumour and float in the blood. Rare, but telling when found.
• Other traces : Bits of RNA and tiny vesicles carry tumour signals too. They add to the picture the blood paints.
• Real time reads : Because it’s just a blood draw, it can be repeated. That turns a snapshot into something closer to a live feed.

It’s one part of a broader workup, and modern robotic cancer surgery is planned alongside this kind of molecular detail when it’s available.

Both find cancer, but they work in opposite ways and answer different questions.

• No needle in the tumour : A tissue biopsy takes a physical sample. A liquid biopsy needs only blood, so it’s far less invasive.
• The whole picture : One tissue sample reads a single spot. Blood catches material from multiple tumour sites at once.
• Repeatable : You can’t keep cutting samples out. But you can draw blood again and again to watch how things shift.
• Still not the gold standard : Tissue remains the way most cancers get confirmed and graded. The blood test supports it, not replaces it.

Knowing which tests done for cancer suit a given case is part of building an accurate diagnosis before any treatment starts.

Dr. Sandeep Nayak is a surgical oncologist with 24 years behind him and a fellowship in laparoscopic and robotic onco-surgery. His diagnostic approach is precision based, pulling together clinical exam, imaging, tissue biopsy and molecular profiling so nothing gets missed or understaged. Liquid biopsy fits into that as one tool among several, used where it genuinely adds something. The test is chosen to fit the case, not the other way round.

Molecular detail matters most in the hard cases. An advanced cancer with an unclear origin, or one that keeps shifting under treatment, is where ctDNA earns its place. Reading how a tumour evolves in real time changes decisions that a single biopsy can’t inform. The right test at the right moment is what keeps a treatment plan on solid ground.

References

1. Liquid biopsy in solid tumours review — National Library of Medicine
2. Liquid biopsy and tumour DNA overview — National Library of Medicine

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.